This list is based on the watchlists of people on Stock Events who follow PLUR.BOATS. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Show more...
FAQ
What is Pluri stock price today?▼
The current price of PLUR.BOATS is $3.45 USD — it has increased by +0% in the past 24 hours. Watch Pluri stock price performance more closely on the chart.
What is Pluri stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pluri stocks are traded under the ticker PLUR.BOATS.
What is Pluri market cap?▼
Today Pluri has the market capitalization of 34.68M
When is the next Pluri earnings date?▼
Pluri is going to release the next earnings report on May 07, 2026.
What is Pluri revenue for the last year?▼
Pluri revenue for the last year amounts to 2.67M USD.
What is Pluri net income for the last year?▼
PLUR.BOATS net income for the last year is -45.17M USD.
When did Pluri complete a stock split?▼
Pluri has not had any recent stock splits.